Objective Evidence of Omalizumab Treatment Assessed by Forced Oscillation (FO)

Amarillo Center for Clinical Research, Amarillo, TX

ABSTRACT

Omalizumab, a monoclonal antibody, is approved for the treatment of moderate to severe asthma in patients who are not well controlled on steroids, whether systemic or high dose inhalation treatment.

METHODS

FO was measured with the oscillation measurement device IOS. This device is a portable device that measures respiratory system impedance and flow. The device was used to measure the respiratory system impedance and flow in patients before and after treatment with omalizumab.

RESULTS

A representative patient is shown in the graph below.

CONCLUSION

FO is a non-invasive and objective test that can be used to assess the effectiveness of asthma treatment. Omalizumab treatment significantly improved the patient's respiratory function, as measured by FO.